PORTFOLIO

We invest in leading healthtech & life sciences companies that are passionate about accelerating cures for the world’s most life threatening conditions and finding solutions to healthcare’s largest cost drivers.

We invest in leading healthtech & life sciences companies that are passionate about accelerating cures for the world’s most life threatening conditions and finding solutions to healthcare’s largest cost drivers.

oo1 copy

OUR PORTFOLIO COMPANIES

All
Fund
  • aMoon I
  • aMoon II
  • aMoon Velocity
Sector
  • BioPharma
  • MedTech
  • Digital
Stage
  • Early-Stage
  • Mid-to-Late Stage
Cluster
  • CNS
  • Oncology
  • Inflammation/Autoimmunity
  • Genomics
  • Musculoskeletal/Orthopedics
  • Anti-infective
  • Cardiovascular & Metabolic
  • APOS MEDICAL ASSETS

    Apos Medical Assets Ltd. (“Apos”) is a global company headquartered in Israel and operating in the U.S., U.K., and Singapore. Founded in 2016, the Company acquired the assets of Apos Medical & Sports Technologies, which developed and commercialized AposTherapy® in 2005. AposTherapy® is a non-invasive, non-pharmaceutical treatment for knee osteoarthritis (OA), lower back, and other lower limb MSK (musculoskeletal) pathologies. Apos Medical Assets distributes AposTherapy® either directly or through MSK service providers to large hospitals and private physical therapy clinics, who provide the treatment to patients. To date, over 65,000 patients have been treated worldwide.

  • AUMMUNE

    Aummune is a pre-clinical cancer therapeutics company which is developing a breakthrough de novo and rapid process, personalized to patient's specific disease parameters at each stage of the therapeutic pathway. The Aummune process is based on a proprietary molecular computation process. Aummune DNA molecules are yielding specific 3D nanostructures that have high binding affinity and inhibit the growth / induce the death of the biological target with a zero or near-zero off-target effect. Aummune has completed development of a robust, reproducible process. A successful proof-of-concept was demonstrated. A strong patent portfolio has been established, and the company is planning to initiate its' clinical program within the next 12 months.

  • AYALA PHARMACEUTICAL

    Ayala Pharmaceutical Inc., a newly founded company, is expected to be a leading precision medicine oncology company based initially on development of AL101 (previously BMS-906024, licensed-in from BMS) for niche patient populations harboring Notch mutations. The Company plans to initiate Phase II trials in orphan oncology indications in patients harboring Notch mutations such as in Adenoid Cystic Carcinoma (ACC). Another opportunity includes a subset of Triple-Negative Breast Cancer (TNBC) patients. On the long term the Company plans to build a pipeline of targeted therapies that could significantly help people living with cancer.

  • BIOLOJIC DESIGN
    • Founded: 2011
    • Company Status: Private
    • Fund: aMoon 2
    • Website: biolojic.com

    Biolojic Design (“Biolojic”) seeks to transform antibody (Ab) drug development through its Ab design, engineering, and optimization platform. Biolojic has developed a computer-guided design process to re-engineer, or “tailor”, natural human Ab templates to bind a new epitope. This epitope-specific approach to Ab design yields antibodies against difficult-to-tackle targets. Biolojic leverages this platform to develop Ab leads with a desired and specific mechanism of action for complex targets such as GPCRs and ion channels.

  • BIONDVAX
    • Founded: 2003
    • Company Status: Public
    • Fund: aMoon 1
    • Website: biondvax.com

    BiondVax is a publicly-traded (TASE 2007, NASDAQ 2015) clinical-stage biopharmaceutical company developing a universal influenza vaccine. The Company’s lead product candidate, M-001, is being clinically evaluated for its potential to confer multi-season and multi-strain protection against seasonal and pandemic human flu viral strains. BiondVax’s proprietary technology utilizes a unique combination of conserved and common peptides from flu virus proteins, activating both arms of the immune system for a cross-protective and long-lasting effect. The Company plans to initiate Phase II clinical trials in the U.S., as well as Phase III trials in E.U. in 2018.

  • CARTIHEAL
    • Founded: 2009
    • Company Status: Private
    • Fund: aMoon 2
    • Website: CartiHeal.com

    CartiHeal develops a cell-free, off-the-shelf implant for the treatment of cartilage and osteochondral defects. Cartilage injuries affect millions of patients around the world, and characteristically cause severe pain and disability. Once damaged, hyaline cartilage has a very limited ability to heal spontaneously. Research indicates that injuries to joint cartilage, if left untreated, may lead to progressive joint changes and early onset of osteoarthritis. The need for a simple, well-tolerated and effective solution for cartilage repair and regeneration represents one of medicine’s most challenging unmet needs. CartiHeal's flagship Agili-C™ implant represents a significant medical breakthrough. This implant has shown to promote regeneration of the articular cartilage and its underlying subchondral bone simultaneously, without the use of external cells, growth factors or other exogenous agents. The cell-free implant is inserted into the joint in a single-stage, minimally-invasive procedure.

  • CTG
    • Founded: 2016
    • Company Status: Private
    • Fund: aMoon 1
    • Website: Coming soon

    CTG Pharma is a privately held, preclinical company, which has developed a revolutionary immunotherapy for cancer patients. CTG's objective is creating a biological solution to enable the use of CAR-T (Chimeric Antigen Receptors for T Cells) and TCR (T-cell receptor) therapies for solid tumors.

  • Curesponse

    Curesponse is a clinical stage cancer diagnostics company that is developing a 3-dimensional tissue culture system for modelling cancer growth and drug response. The platform preserves the cancer tissue architecture (including vasculature and immune system) accurately reflecting the cancer growth found in the body. The company is harnessing the technology to create a personalized cancer diagnostic assay that can be used to determine drug response for a specific individual's tumor type. Patients and clinicians can send samples of their tumor to be tested with a panel of anti-cancer therapies predetermined by genomic screening and physician assessment.

  • DAYTWO
    • Founded: 2015
    • Company Status: Private
    • Fund: aMoon 1
    • Website: daytwo.com

    DayTwo develops software that provides personalized nutrition to enable people to live healthier lives and maintain normal blood sugar levels. The Company leverages its Gut Microbiome Platform™ to conduct advanced genetic sequencing of gut microbiome and big data analytics to predict an individual’s glycemic response based on gut microbiome and other clinical parameters. DayTwo translates this data into personalized, actionable insights primarily aimed to prevent and treat metabolic diseases such as diabetes and obesity. The Company seeks to build the largest and most detailed microbiome database available, providing a platform for a variety of microbiome-based preventive, diagnostic, and therapeutic products.

  • IGENTIFY
    • Founded: 2016
    • Company Status: Private
    • Fund: aMoon 1
    • Website: igentify.com

    Igentify, founded in 2016, is a privately held company that strives to import genomic molecular results directly from sophisticated laboratory testing equipment and analyze it using a state of the art genomic database and algorithms. The Company can then combine it with comprehensive information gathered online from patients, at their convenience, to create personalized, medically supervised, genetic counseling. Igentify’s system uses advanced algorithms to produce definitive results in a fraction of the time and cost of traditional methods. Igentify follows precision medicine principles to enable patients to make better, more informed health decisions by bridging the gap between tests, analysis and patient comprehension. Health care providers receive detailed reports using familiar templates of their choice. Smart personalized videos explain conditions to patients who can decide on follow up actions.

  • KARIUS
    • Founded: 2016
    • Company Status: Private
    • Fund: aMoon 1
    • Website: kariusdx.com

    Karius is a clinical stage, life science diagnostics (dx) company leveraging proprietary technology and know-how to develop its “Digital Culture test”, a liquid biopsy dx test of infectious diseases. The Company, aims to enable clinicians to rapidly diagnose infectious diseases by detecting the DNA of over 1,250 pathogens from a standard blood draw. This is enabled by detecting cell-free DNA (cfDNA), a broad term which describes DNA that is freely circulating in the bloodstream. Typically, Karius’s technology uses DNA sequencing test, proprietary molecular biology, next–generation sequencing, and data analytics after a single patient blood draw.

  • MAPI PHARMA

    Mapi Pharma is a clinical-stage pharmaceutical company primarily engaged in the development of life-cycle management (LCM) products intended for long acting depot injections with extended-release formulations of existing commercially-successful products. In addition, the Company is involved in the development of generic drugs that include complex Active Pharmaceutical Ingredients (APIs) and finished dosage formulations (FDFs). The company’s lead LCM product, Glatiramer Acetate (GA), ‘Copaxone’, monthly depot, improves treatment administration for multiple sclerosis (MS) patients by increasing compliance and reducing treatment burden. The Company’s development portfolio includes 4 LCM products, 15 products and 1 New Chemical Entity (NCE), as well as additional collaborations with leading pharma companies.

  • Medial EarlySign (“EarlySign”) develops a predictive care engine driven by medical data. The Company leverages a machine learning-based artificial intelligence (AI) infrastructure designed to detect early warning signals and health risks, or ‘blind spots’, in routine electronic health records (EHR). By exposing these hidden signals, EarlySign enables providers to identify individuals at risk of a range of health conditions, effectively allocate resources to these at-risk populations via personalized care management plans, and increase the likelihood of successful diagnosis and early intervention. The Company’s first commercialized tool, ColonFlag™, has been successfully implemented by integrated delivery networks (IDNs) to identify individuals with an elevated probability for lower-gastrointestinal disorders, enabling organizations to effectively contact, test, and treat these patients. It seeks to expand to a wider range of outcomes, from early detection of cancers to metabolic and other medical conditions.

  • MDSG

    Medical technologies innovation platform.

  • NOBIO
    • Founded: 2015
    • Company Status: Private
    • Fund: aMoon 1
    • Website: nobio.com

    Nobio™ is a privately held company involved in the development of antimicrobial particles that can be permanently embedded in multiple products and materials to perpetually inhibit formation of biofilm on their surface. A biofilm is a group of microorganisms in which cells stick to each other and to a surface.
    Nobio has developed proprietary particles with antimicrobial activity that bind permanently with a broad range of materials. Each particle is covered with a high concentration of antimicrobial structures to generate a powerful collective effect. As bacteria approach, each particle exerts strong electrostatic forces to attract the bacteria and apply stress to its membrane, causing it to deactivate and die. The Nobio particles have the capability to be embedded in a wide range of materials during its production. Once in the material they remain there permanently without altering its intended properties. According to the company, A small concentration of highly active Nobio particles, can transform many products into antimicrobial, permanently protecting them against biofilm formation.

  • PHARMA TWO B
    • Founded: 2007
    • Company Status: Private
    • Fund: aMoon 1
    • Website: pharma2b.com

    Pharma Two B is focused on developing novel, synergistic, combination products based on previously approved drugs. The company established a platform for identification, characterization and development of low dose combinations that seek to offer high therapeutic effects with improved safety profiles, that would lead to clinically and commercially added value products. The combinations are aimed for the 505(b)(2) approval pathway allowing a shorter regulatory process to registration. The Company’s lead product in development, P2B001, is currently in phase III clinical trial, as a novel treatment for early stage Parkinson’s Disease (PD). Further studies with P2B001 in advanced PD patients’ population are planned.

  • REGENERA

    Regenera is a clinical-stage biopharmaceutical company focused on developing a novel drug for neurological disorders. The company’s lead product, RPh201, is a botanical extract from gum mastic, with regenerative and functional recovery benefits observed in pre-clinical and clinical studies. The Company recently completed a Phase 2a clinical trial in patients with previous Nonarteritic Anterior Ischemic Optic Neuropathy (NAION).

  • TA GEZA

    Coming soon...

OUR PORTFOLIO COMPANIES

All
Fund
  • aMoon I
  • aMoon II
  • aMoon Velocity
Sector
  • BioPharma
  • MedTech
  • Digital
  • APOS MEDICAL ASSETS
    • Founded: 2004
    • Company Status: Private
    • Fund: aMoon 1
    • Website: apostherapy.com

    Apos Medical Assets Ltd. (“Apos”) is a global company headquartered in Israel and operating in the U.S., U.K., and Singapore. Founded in 2016, the Company acquired the assets of Apos Medical & Sports Technologies, which developed and commercialized AposTherapy® in 2005. AposTherapy® is a non-invasive, non-pharmaceutical treatment for knee osteoarthritis (OA), lower back, and other lower limb MSK (musculoskeletal) pathologies. Apos Medical Assets distributes AposTherapy® either directly or through MSK service providers to large hospitals and private physical therapy clinics, who provide the treatment to patients. To date, over 65,000 patients have been treated worldwide.

  • AUMMUNE

    Aummune is a pre-clinical cancer therapeutics company which is developing a breakthrough de novo and rapid process, personalized to patient's specific disease parameters at each stage of the therapeutic pathway. The Aummune process is based on a proprietary molecular computation process. Aummune DNA molecules are yielding specific 3D nanostructures that have high binding affinity and inhibit the growth / induce the death of the biological target with a zero or near-zero off-target effect. Aummune has completed development of a robust, reproducible process. A successful proof-of-concept was demonstrated. A strong patent portfolio has been established, and the company is planning to initiate its' clinical program within the next 12 months.

  • AYALA PHARMACEUTICAL
    • Founded: 2017
    • Company Status: Private
    • Fund: aMoon 2
    • Website: Coming soon

    Ayala Pharmaceutical Inc., a newly founded company, is expected to be a leading precision medicine oncology company based initially on development of AL101 (previously BMS-906024, licensed-in from BMS) for niche patient populations harboring Notch mutations. The Company plans to initiate Phase II trials in orphan oncology indications in patients harboring Notch mutations such as in Adenoid Cystic Carcinoma (ACC). Another opportunity includes a subset of Triple-Negative Breast Cancer (TNBC) patients. On the long term the Company plans to build a pipeline of targeted therapies that could significantly help people living with cancer.

  • BIOLOJIC DESIGN
    • Founded: 2011
    • Company Status: Private
    • Fund: aMoon 2
    • Website: biolojic.com

    Biolojic Design (“Biolojic”) seeks to transform antibody (Ab) drug development through its Ab design, engineering, and optimization platform. Biolojic has developed a computer-guided design process to re-engineer, or “tailor”, natural human Ab templates to bind a new epitope. This epitope-specific approach to Ab design yields antibodies against difficult-to-tackle targets. Biolojic leverages this platform to develop Ab leads with a desired and specific mechanism of action for complex targets such as GPCRs and ion channels.

  • BIONDVAX
    • Founded: 2003
    • Company Status: Public
    • Fund: aMoon 1
    • Website: biondvax.com

    BiondVax is a publicly-traded (TASE 2007, NASDAQ 2015) clinical-stage biopharmaceutical company developing a universal influenza vaccine. The Company’s lead product candidate, M-001, is being clinically evaluated for its potential to confer multi-season and multi-strain protection against seasonal and pandemic human flu viral strains. BiondVax’s proprietary technology utilizes a unique combination of conserved and common peptides from flu virus proteins, activating both arms of the immune system for a cross-protective and long-lasting effect. The Company plans to initiate Phase II clinical trials in the U.S., as well as Phase III trials in E.U. in 2018.

  • CARTIHEAL
    • Founded: 2009
    • Company Status: Private
    • Fund: aMoon 2
    • Website: CartiHeal.com

    CartiHeal develops a cell-free, off-the-shelf implant for the treatment of cartilage and osteochondral defects. Cartilage injuries affect millions of patients around the world, and characteristically cause severe pain and disability. Once damaged, hyaline cartilage has a very limited ability to heal spontaneously. Research indicates that injuries to joint cartilage, if left untreated, may lead to progressive joint changes and early onset of osteoarthritis. The need for a simple, well-tolerated and effective solution for cartilage repair and regeneration represents one of medicine’s most challenging unmet needs. CartiHeal's flagship Agili-C™ implant represents a significant medical breakthrough. This implant has shown to promote regeneration of the articular cartilage and its underlying subchondral bone simultaneously, without the use of external cells, growth factors or other exogenous agents. The cell-free implant is inserted into the joint in a single-stage, minimally-invasive procedure.

  • CTG
    • Founded: 2016
    • Company Status: Private
    • Fund: aMoon 1
    • Website: Coming soon

    CTG Pharma is a privately held, preclinical company, which has developed a revolutionary immunotherapy for cancer patients. CTG's objective is creating a biological solution to enable the use of CAR-T (Chimeric Antigen Receptors for T Cells) and TCR (T-cell receptor) therapies for solid tumors.

  • Curesponse

     

    Curesponse is a clinical stage cancer diagnostics company that is developing a 3-dimensional tissue culture system for modelling cancer growth and drug response. The platform preserves the cancer tissue architecture (including vasculature and immune system) accurately reflecting the cancer growth found in the body. The company is harnessing the technology to create a personalized cancer diagnostic assay that can be used to determine drug response for a specific individual's tumor type. Patients and clinicians can send samples of their tumor to be tested with a panel of anti-cancer therapies predetermined by genomic screening and physician assessment.

  • DAYTWO
    • Founded: 2015
    • Company Status: Private
    • Fund: aMoon 1
    • Website: daytwo.com

    DayTwo develops software that provides personalized nutrition to enable people to live healthier lives and maintain normal blood sugar levels. The Company leverages its Gut Microbiome Platform™ to conduct advanced genetic sequencing of gut microbiome and big data analytics to predict an individual’s glycemic response based on gut microbiome and other clinical parameters. DayTwo translates this data into personalized, actionable insights primarily aimed to prevent and treat metabolic diseases such as diabetes and obesity. The Company seeks to build the largest and most detailed microbiome database available, providing a platform for a variety of microbiome-based preventive, diagnostic, and therapeutic products.

  • IGENTIFY
    • Founded: 2016
    • Company Status: Private
    • Fund: aMoon 1
    • Website: igentify.com

    Igentify, founded in 2016, is a privately held company that strives to import genomic molecular results directly from sophisticated laboratory testing equipment and analyze it using a state of the art genomic database and algorithms. The Company can then combine it with comprehensive information gathered online from patients, at their convenience, to create personalized, medically supervised, genetic counseling. Igentify’s system uses advanced algorithms to produce definitive results in a fraction of the time and cost of traditional methods. Igentify follows precision medicine principles to enable patients to make better, more informed health decisions by bridging the gap between tests, analysis and patient comprehension. Health care providers receive detailed reports using familiar templates of their choice. Smart personalized videos explain conditions to patients who can decide on follow up actions.

  • KARIUS
    • Founded: 2016
    • Company Status: Private
    • Fund: aMoon 1
    • Website: kariusdx.com

    Karius is a clinical stage, life science diagnostics (dx) company leveraging proprietary technology and know-how to develop its “Digital Culture test”, a liquid biopsy dx test of infectious diseases. The Company, aims to enable clinicians to rapidly diagnose infectious diseases by detecting the DNA of over 1,250 pathogens from a standard blood draw. This is enabled by detecting cell-free DNA (cfDNA), a broad term which describes DNA that is freely circulating in the bloodstream. Typically, Karius’s technology uses DNA sequencing test, proprietary molecular biology, next–generation sequencing, and data analytics after a single patient blood draw.

  • MAPI PHARMA
    • Founded: 2008
    • Company Status: Private
    • Fund: aMoon 1
    • Website: mapi-pharma.com

    Mapi Pharma is a clinical-stage pharmaceutical company primarily engaged in the development of life-cycle management (LCM) products intended for long acting depot injections with extended-release formulations of existing commercially-successful products. In addition, the Company is involved in the development of generic drugs that include complex Active Pharmaceutical Ingredients (APIs) and finished dosage formulations (FDFs). The company’s lead LCM product, Glatiramer Acetate (GA), ‘Copaxone’, monthly depot, improves treatment administration for multiple sclerosis (MS) patients by increasing compliance and reducing treatment burden. The Company’s development portfolio includes 4 LCM products, 15 products and 1 New Chemical Entity (NCE), as well as additional collaborations with leading pharma companies.

  • MDSG

    Medical technologies innovation platform.

  • NOBIO
    • Founded: 2015
    • Company Status: Private
    • Fund: aMoon 1
    • Website: nobio.com

    Nobio™ is a privately held company involved in the development of antimicrobial particles that can be permanently embedded in multiple products and materials to perpetually inhibit formation of biofilm on their surface. A biofilm is a group of microorganisms in which cells stick to each other and to a surface.
    Nobio has developed proprietary particles with antimicrobial activity that bind permanently with a broad range of materials. Each particle is covered with a high concentration of antimicrobial structures to generate a powerful collective effect. As bacteria approach, each particle exerts strong electrostatic forces to attract the bacteria and apply stress to its membrane, causing it to deactivate and die. The Nobio particles have the capability to be embedded in a wide range of materials during its production. Once in the material they remain there permanently without altering its intended properties. According to the company, A small concentration of highly active Nobio particles, can transform many products into antimicrobial, permanently protecting them against biofilm formation.

  • PHARMA TWO B
    • Founded: 2007
    • Company Status: Private
    • Fund: aMoon 1
    • Website: pharma2b.com

    Pharma Two B is focused on developing novel, synergistic, combination products based on previously approved drugs. The company established a platform for identification, characterization and development of low dose combinations that seek to offer high therapeutic effects with improved safety profiles, that would lead to clinically and commercially added value products. The combinations are aimed for the 505(b)(2) approval pathway allowing a shorter regulatory process to registration. The Company’s lead product in development, P2B001, is currently in phase III clinical trial, as a novel treatment for early stage Parkinson’s Disease (PD). Further studies with P2B001 in advanced PD patients’ population are planned.

  • REGENERA

    Regenera is a clinical-stage biopharmaceutical company focused on developing a novel drug for neurological disorders. The company’s lead product, RPh201, is a botanical extract from gum mastic, with regenerative and functional recovery benefits observed in pre-clinical and clinical studies. The Company recently completed a Phase 2a clinical trial in patients with previous Nonarteritic Anterior Ischemic Optic Neuropathy (NAION).

  • TA GEZA

    Coming soon...